Jupiter Medical Center Appoints Dr. Charles Murphy as Chief Quality and Patient Safety Officer

Dr. Charles Murphy: Jupiter Medical Center, the number one ranked hospital for safety, quality and patient satisfaction in Palm Beach County and the Treasure Coast region, today announced the appointment of Charles Murphy, Jr., MD, CPPS as Chief Quality and Patient Safety Officer.

Previously, Dr. Murphy served as associate chief patient safety officer and medical director of intensive care units at Duke University Health System. Under his leadership, all three acute care hospitals in the Duke Health system received ‘A’ safety grades from The Leapfrog Group for providing the highest standard in patient safety and quality. In 2014, Dr. Murphy was selected by the American Hospital Association – National Patient Safety Foundation Safety Leadership for fellowship. He also received an award for Most Improved Patient Safety Culture from Cardiothoracic Surgery Collaborative at Duke Hospital.

“We are delighted to welcome Dr. Murphy in leading our patient safety and quality initiatives,” said Dr. Amit Rastogi, president and CEO of Jupiter Medical Center. “Aside from his remarkable experiences in leading safety and quality initiatives at world-class health systems, including Duke University Health System and Inova, Dr. Murphy will bring a physician’s perspective to how we continuously improve our patient experience and outcomes.”

Dr. Murphy most recently served as chief patient safety officer at the Inova Heart and Vascular Institute based in Falls Church, Virginia. During his four-year tenure, he attained 20 to 30 percent reductions in patient harm year over year. His leadership at Inova resulted in achieving a two percent improvement in the hospital’s Agency for Healthcare Research and Quality (AHRQ) safety culture scores from 2017 to 2019 and expanded the Extracorporeal Membrane Oxygenation (ECMO) program from 10 to 100 cases per year as the Executive Leader. He also spearheaded the development of a multidisciplinary shock team with an increase in survival from 50 to 70 percent.

“I am pleased to join Jupiter Medical Center, Palm Beach County’s number one ranked hospital for quality, safety and patient satisfaction,” said Charles Murphy, Jr., MD, CPPS. “We will continue to build on Jupiter Medical Center’s well-deserved reputation and unwavering commitment to providing the highest standards of patient care.”

Since 2014, Murphy has served as a Board Member for the Foundation for the Advancement of Cardiovascular And Thoracic Critical Care. He has received certifications from the American Board of Surgery, American Board of Thoracic Surgery, American Board of Surgery Surgical Critical Care, and Board for Professionals in Patient Safety. Dr. Murphy is also a member of several highly-regard professional medical committees, including the Society of Critical Care Medicine, Society of Thoracic Surgery, Foundation for the Advancement of Cardiovascular And Thoracic Critical Care, American Society of Professionals in Patient Safety, American Association of Physician Leadership, among others.

Murphy earned a Doctor of Medicine from Duke University School of Medicine in Durham, North Carolina, and a Bachelor of Science with honors in Biology from Loyola University, New Orleans. Dr. Murphy received his post-graduate training at Duke University Medical Center.

In May of 2020, Jupiter Medical Center announced it had been awarded an ‘A’ safety grade rating and is the only hospital in Palm Beach County to earn the top rating for the Spring of 2020. The ‘A’ safety rating awarded by The Leapfrog Group, a national nonprofit focused on rating and measuring hospital safety, quality and affordability, is considered ‘the gold standard measure of patient safety.’ The Leapfrog Group has also recognized Jupiter Medical Center as a “Top Hospital,” an annual distinction earned by only six percent of hospitals nationwide. Additionally, Jupiter Medical Center remains the only hospital in Palm Beach, Martin, St. Lucie and Indian River counties to receive a 4-star safety and quality rating from the Centers for Medicare & Medicaid Services (CMS).

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version